Welcome to Paid Research Studies




  • Conditions:   Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Biological: Aldesleukin;   Biological: Pembrolizumab
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Melanoma;   Stage III Mucosal Melanoma of the Head and Neck;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma;   Stage IVA Mucosal Melanoma of the Head and Neck;   Stage IVB Mucosal Melanoma of the Head and Neck;   Stage IVC Mucosal Melanoma of the Head and Neck
    Interventions:   Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsors:   Rutgers, The State University of New Jersey;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   HLA-A*0201 Positive Cells Present;   HLA-A*24:02 Positive Cells Present;   Metastatic Uveal Melanoma;   Uveal Melanoma Metastatic in the Liver
    Interventions:   Biological: Aldesleukin;   Biological: Autologous CD8+ SLC45A2-specific T Lymphocytes;   Drug: Cyclophosphamide;   Biological: Ipilimumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Ulcerative Colitis
    Intervention:   Drug: Interleukin-2 (aldesleukin).
    Sponsor:   Scott Snapper
    Recruiting

  • Conditions:   COL6A3 Positive;   HLA-A*0201 Positive Cells Present;   PRAME Positive;   Recurrent Ovarian Carcinoma
    Interventions:   Biological: Aldesleukin;   Drug: CD8-Positive T-Lymphocyte;   Drug: Cyclophosphamide;   Procedure: Leukapheresis;   Biological: Utomilumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
    Interventions:   Biological: Aldesleukin;   Biological: CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: NGFR-transduced Autologous T Lymphocytes;   Other: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Non-Small Cell Lung Cancer;   Squamous Cell Carcinoma;   Advanced NSCLC;   Adenosquamous Carcinoma;   Adenocarcinomas
    Interventions:   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Young TIL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
    Interventions:   Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: NGFR-transduced Autologous T Lymphocytes;   Biological: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Liver Transplantation
    Intervention:   Biological: Interleukin-2
    Sponsor:   Beth Israel Deaconess Medical Center
    Recruiting

  • Conditions:   Bone Sarcoma;   Dedifferentiated Chondrosarcoma;   Giant Cell Tumor of Bone;   Malignancy in Giant Cell Tumor of Bone;   Ovarian Carcinosarcoma;   Platinum-Resistant Ovarian Carcinoma;   Recurrent Osteosarcoma;   Refractory Osteosarcoma;   Refractory Ovarian Carcinoma;   Soft Tissue Sarcoma;   Undifferentiated High Grade Pleomorphic Sarcoma of Bone
    Interventions:   Biological: Aldesleukin;   Biological: Autologous Tumor Infiltrating Lymphocytes LN-145;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   HLA-A2 Positive Cells Present;   Metastatic Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Brain
    Interventions:   Biological: Aldesleukin;   Biological: Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis
    Sponsors:   Albert Einstein College of Medicine;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Papillomavirus Infections;   Cervical Intraepithelial Neoplasia;   Carcinoma In Situ;   Vulvar Neoplasms;   Vulvar Diseases
    Interventions:   Biological: E7 TCR cells;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Glioblastoma;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Breast Cancer;   Gastrointestinal/Genitourinary Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: Individual Patient TCR-Transduced PBL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Melanoma;   Meningioma;   Breast Cancer;   Non-Small Cell Lung Cancer;   Hepatocellular Cancer
    Interventions:   Biological: Anti-NY ESO-1 mTCR PBL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cervical Cancer;   Renal Cancer;   Urothelial Cancer;   Melanoma;   Breast Cancer
    Interventions:   Biological: Anti-MAGE-A3-DP4 TCR PBL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: high dose Aldesleukin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Metastatic Melanoma
    Interventions:   Drug: Aldesleukin;   Drug: Nivolumab: Cohort 1;   Drug: Nivolumab: Cohort 2
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   HLA-A*0201 Positive Cells Present;   HLA-DP4 Positive Cells Present;   Platinum-Resistant Ovarian Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma
    Interventions:   Biological: Aldesleukin;   Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes;   Other: Cellular Therapy;   Drug: Melphalan
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Gastrointestinal Cancer;   Pancreatic Cancer;   Gastric Cancer;   Colon Cancer;   Rectal Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: anti-KRAS G12D mTCR PBL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Decitabine;   Biological: Genetically Engineered NY-ESO-1-specific T Lymphocytes;   Other: Laboratory Biomarker Analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pancreatic Cancer;   Renal Cell Cancer;   Breast Cancer;   Melanoma;   Ovarian Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: Anti-hCD70 CAR transduced PBL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pancreatic Cancer;   Gastric Cancer;   Gastrointestinal Cancer;   Colon Cancer;   Rectal Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: anti-KRAS G12V mTCR;   Drug: Aldesleukin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Colorectal Adenocarcinoma;   Metastatic Cholangiocarcinoma;   Metastatic Colorectal Carcinoma;   Metastatic Digestive System Carcinoma;   Metastatic Esophageal Carcinoma;   Metastatic Gastric Carcinoma;   Metastatic Pancreatic Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IV Esophageal Cancer AJCC v7;   Stage IV Gastric Cancer AJCC v7;   Stage IV Pancreatic Cancer AJCC v6 and v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
    Interventions:   Biological: Adoptive Immunotherapy;   Biological: Aldesleukin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Synovial Sarcoma;   Myxoid Liposarcoma;   HLA-A*0201 Positive Cells Present;   NY-ESO-1 Positive Tumor Cells Present;   Recurrent Myxoid Liposarcoma;   Recurrent Synovial Sarcoma
    Interventions:   Biological: Aldesleukin;   Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes;   Drug: Cyclophosphamide;   Biological: Dendritic Cell-targeting Lentiviral Vector ID-LV305;   Drug: Immunotherapeutic Combination Product CMB305
    Sponsors:   M.D. Anderson Cancer Center;   Immune Design;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cancer;   Solid Tumor
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: IMA101 product;   Biological: Recombinant human interleukin-2;   Diagnostic Test: IMADetect;   Drug: Atezolizumab
    Sponsors:   Immatics US, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   HIV Infection
    Intervention:   Drug: Recombinant Interleukin-2
    Sponsor:   Case Western Reserve University
    Recruiting

  • Condition:   Metastatic Melanoma
    Interventions:   Drug: Tumor Infiltrating Lymphocytes;   Drug: Nivolumab and Ipilimumab
    Sponsor:   Yale University
    Recruiting

  • Conditions:   Metastatic Colorectal Cancer;   Progressive Glioblastoma;   Metastatic Pancreatic Cancer;   Metastatic Ovarian Cancer;   Metastatic Breast Cancer
    Interventions:   Biological: Young TIL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Pembrolizumab (Keytruda)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Drug: Entinostat;   Drug: Interleukin-2
    Sponsors:   Roberto Pili;   Indiana University Melvin and Bren Simon Cancer Center;   Prometheus Laboratories;   Syndax Pharmaceuticals
    Recruiting

  • Conditions:   Biliary Tract Cancer;   Cholangiocarcinoma;   Biliary Tract Neoplasms
    Intervention:   Biological: Tumor Infiltrating Lymphocytes (TIL)
    Sponsor:   Udai Kammula
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Erythroid Leukemia;   Acute Megakaryoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blasts Under 20 Percent of Bone Marrow Nucleated Cells;   Blasts Under 20 Percent of Peripheral Blood White Cells;   Chronic Myelomonocytic Leukemia;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Biological: Aldesleukin;   Biological: Allogeneic CD56-positive CD3-negative Natural Killer Cells;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Uveal Neoplasms;   Melanoma, Uveal
    Intervention:   Biological: Tumor Infiltrating Lymphocytes (TIL)
    Sponsor:   Udai Kammula
    Recruiting

  • Condition:   Renal Cell Carcinoma
    Interventions:   Biological: High Dose IL-2;   Radiation: SBRT
    Sponsors:   Providence Health & Services;   Prometheus Laboratories;   Cytokine Working Group
    Recruiting

  • Condition:   Malignant Neoplasm
    Interventions:   Biological: aldesleukin;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL;   Biological: dendritic cell vaccine therapy;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography
    Sponsor:   Jonsson Comprehensive Cancer Center
    Recruiting

  • Conditions:   Adult Solid Neoplasm;   Childhood Solid Neoplasm;   Metastatic Neoplasm
    Interventions:   Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL;   Biological: NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine;   Procedure: Positron Emission Tomography
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   HLA-A*0201 Positive Cells Present;   Locally Advanced Malignant Neoplasm;   NY-ESO-1 Positive;   Unresectable Malignant Neoplasm
    Interventions:   Other: 18F-FHBG;   Biological: Aldesleukin;   Drug: Busulfan;   Biological: Cellular Therapy;   Procedure: Computed Tomography;   Biological: Filgrastim;   Drug: Fludarabine;   Procedure: Leukapheresis;   Drug: Plerixafor;   Procedure: Positron Emission Tomography
    Sponsors:   Jonsson Comprehensive Cancer Center;   California Institute for Regenerative Medicine (CIRM);   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Metastatic Melanoma
    Interventions:   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Young Tumor Infiltrating Lymphocytes (Young TIL);   Drug: Pembrolizumab (Keytruda)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Diabetes Mellitus, Type 1;   Hypoglycemia;   Autoimmune Diseases;   Diabetes Mellitus
    Interventions:   Drug: Anti-Thymocyte Globulin (ATG);   Drug: Placebo;   Drug: Pegylated GCSF;   Drug: Interleukin 2;   Drug: Etanercept;   Drug: Exenatide
    Sponsors:   Camillo Ricordi and Jay Skyler;   Diabetes Research Institute Foundation
    Not yet recruiting

  • Condition:   Melanoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldeslaukin;   Drug: Pembrolizumab;   Biological: young TIL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   HLA-A*0201 Positive Cells Present;   NY-ESO-1 Positive Tumor Cells Present;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Radiation: 18F-FHBG;   Biological: Aldesleukin;   Biological: Cellular Therapy;   Procedure: Computed Tomography;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Procedure: Leukapheresis;   Drug: Melphalan;   Drug: Plerixafor;   Procedure: Positron Emission Tomography
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI);   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Condition:   Leukemia, Myeloid, Acute
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Procedure: Leukapheresis;   Biological: Cytokine-induced killer cells;   Biological: IL-2;   Drug: ALT-803;   Procedure: Peripheral blood for correlative studies;   Procedure: Bone marrow for correlative studies
    Sponsors:   Washington University School of Medicine;   American Society of Clinical Oncology;   American Society of Hematology;   Gabrielle's Angel Foundation;   The Leukemia and Lymphoma Society;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Melanoma
    Interventions:   Biological: Dendritic Cell Immunization;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T-Cells;   Biological: Interleukin-2;   Drug: Mesna;   Biological: Intrathecal T-Cells;   Biological: Intrathecal Interleukin-2
    Sponsors:   M.D. Anderson Cancer Center;   Prometheus Laboratories;   Key Biologics, LLC;   National Cancer Institute (NCI);   Adelson Medical Research
    Recruiting

  • Conditions:   Gastric Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Sarcoma;   Mesothelioma;   Neuroendocrine Tumors;   Squamous Cell Cancer;   Merkel Cell Carcinoma;   Mismatch Repair Deficiency;   Microsatellite Instability
    Interventions:   Biological: Tumor Infiltrating Lymphocytes (TIL);   Drug: Fludarabine + Cyclophosphamide combination
    Sponsor:   Udai Kammula
    Not yet recruiting

  • Condition:   METASTATIC NON-SMALL CELL LUNG CANCER
    Interventions:   Drug: Intralesional IL-2;   Drug: Nivolumab;   Drug: Pembrolizumab;   Radiation: Radiotherapy
    Sponsor:   University of California, Davis
    Recruiting

  • Conditions:   Disseminated Neuroblastoma;   Recurrent Neuroblastoma
    Interventions:   Biological: IL-2;   Biological: GD2Bi-aATC;   Biological: GM-CSF;   Other: laboratory evaluations of immune responses
    Sponsors:   University of Virginia;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Refractory Cancer;   Recurrent Cancer;   Solid Tumor, Adult;   Cancer
    Interventions:   Biological: IMA203 Product;   Device: IMADetect
    Sponsors:   Immatics US, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Solid Tumor, Adult;   Cancer;   Hepatocellular Carcinoma;   Hepatocellular Cancer;   Nonsmall Cell Lung Cancer;   Liver Cancer;   Lung Cancer
    Interventions:   Drug: IMA202 Product;   Device: IMA_Detect
    Sponsors:   Immatics US, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Solid Tumor;   Cancer;   Head and Neck Squamous Cell Carcinoma;   Non-small Cell Lung Cancer
    Interventions:   Biological: IMA201 Product;   Diagnostic Test: IMA_Detect;   Diagnostic Test: ACT-HLA
    Sponsors:   Immatics US, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Childhood Ganglioneuroblastoma;   Childhood Neuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   NMYC Gene Amplification;   Recurrent Neuroblastoma
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   High-Risk Neuroblastoma;   NMYC Gene Amplification
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Dexrazoxane;   Biological: Dinutuximab;   Drug: Doxorubicin;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Drug: Isotretinoin;   Drug: Melphalan;   Biological: Sargramostim;   Drug: Thiotepa;   Drug: Topotecan;   Drug: Vincristine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin;   Device: CliniMACS
    Sponsors:   St. Jude Children's Research Hospital;   Cookies for Kids' Cancer;   CURE Childhood Cancer, Inc.
    Recruiting

  • Conditions:   Non-Small Cell Lung Cancer;   Metastatic Non-small Cell Lung Cancer;   Squamous Cell Carcinoma;   Advanced NSCLC;   Adenosquamous Carcinoma;   Adenocarcinomas
    Interventions:   Procedure: Tumor-infiltrating Lymphocytes (TIL);   Drug: Nivolumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Tumor-infiltrating Lymphocyte Therapy;   Drug: Interleukin-2 (IL2)
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb;   Prometheus Inc.;   Stand Up To Cancer;   Iovance Biotherapeutics, Inc.
    Recruiting